CL vs VVVV: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CL is the larger of the two ($78.79B market cap): the incumbent the market prices for continued execution (24.17x forward earnings, beta 0.31). VVVV is the smaller challenger ($786.28M): more room to run, but more to prove. If the story you believe is CL's (Oral-care leadership and emerging markets), CL is the more direct way to own it; if it is VVVV's (More U.S. practices, and more use per practice), VVVV is.
Before you buy: how CL and VVVV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CL and VVVV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CL and VVVV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Colgate-Palmolive (CL) do?
Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.
What does vVARDIS Holding AG (VVVV) do?
vVARDIS Holding AG is a dental products company based in Zug, Switzerland, run by its co-founders and co-CEOs Haley and Goly Abivardi, two dentists who previously ran a chain of Swiss clinics. Its business is one product family, Curodont, a peptide-containing liquid a dentist applies to an early-stage cavity in a few minutes, without drilling or anaesthetic. The peptides form a scaffold inside the lesion that lets minerals from saliva rebuild the enamel. In the United States the product is sold as Curodont Repair Fluoride Plus, which the FDA regulates as an over-the-counter drug because of its sodium fluoride content. That route got it to market quickly, and it also means the FDA has made no finding on its safety or effectiveness.
CL vs VVVV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.
- VVVV drivers: More U.S. practices, and more use per practice; AI cavity detection as a referral channel.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. For VVVV, almost all revenue comes from one product family, and in the U.S.
CL or VVVV: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate CL from VVVV. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CL and VVVV guides.
CL vs VVVV: the full fundamentals
CL. At about $99.19 on November 20, 2026, Colgate trades near 39x trailing GAAP earnings, a figure inflated by the small reported loss in the fourth quarter of 2025, and around 24x forward earnings, a defensive-staples premium that widened as the shares rose about 27.7% this year. Consensus calls for 2026 EPS near $3.92 on revenue of about $21.4 billion and 2027 EPS near $4.10, with fourth-quarter results expected around late January 2027 against an EPS estimate of $0.98. The 20 covering analysts carry a mean price target around $101.70, close to the current price, and a buy-leaning rating.
VVVV. The market value depends on how shares are counted. After the IPO there are about 38.6 million Class A shares plus 143.9 million Class B voting shares held by the founders, but each Class B share carries one-tenth the economic rights of a Class A share, so it counts as about 14.4 million Class A equivalents. Some early press reports quoted a valuation above $4 billion by counting Class B shares as full shares. On ~53.0 million economic shares at ~$14.81 the company is worth ~$0.78 billion, about 14 times trailing revenue of ~$56 million and about 26 times 2025 revenue. No analyst coverage exists yet; the underwriters' quiet period typically ends 25 days after the IPO, which points to early December 2026.
Headline figures (approximate, November 2026): CL shows revenue (ttm) ~$21.3 billion, revenue growth (latest quarter, yoy) ~4.6%, gross / operating margin ~61% / ~21%, net income (ttm) ~$2.05 billion; VVVV shows revenue (ttm through september 2026, preliminary) ~$56M (Q4 2025 plus 9M 2026 midpoint), revenue (9m 2026, preliminary) ~$47.7M to $49.2M, up ~114% to 121%, gross margin (9m 2026, preliminary) ~86%, net loss (9m 2026, preliminary) ~$39.7M to $41.3M (adjusted EBITDA ~-$9.3M).
The bottom line: CL vs VVVV
CL and VVVV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CL and VVVV exposure against your real portfolio. It is not an investment adviser.
Wondering how CL or VVVV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Colgate-Palmolive
Ask Walnut's AI anything about CL and see how it fits what you own.
FAQ
What is the difference between CL and VVVV?
+
Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. vVARDIS Holding AG is a dental products company based in Zug, Switzerland, run by its co-founders and co-CEOs Haley and Goly Abivardi, two dentists who previously ran a chain of Swiss clinics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CL or VVVV the better stock?
+
Neither is universally better. CL is the larger incumbent; VVVV is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CL or VVVV?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CL and VVVV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CL vs VVVV?
+
CL: Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. It faces intense competition from Procter and Gamble, Unilever, and private-label brands, plus pressure from retailers. Heavy emerging-market exposure brings currency volatility that can erode reported results. Input-cost inflation, the rise of private label during cost-of-living squeezes, and the challenge of sustaining pricing without losing volume all weigh on the outlook. The defensive premium valuation can also compress when investors rotate toward higher-growth or cyclical names; part of the 2026 rally came from money leaving AI stocks, flows that can reverse. Reported earnings are also more volatile than the brand story implies: the fourth quarter of 2025 swung to a small GAAP net loss, which keeps the trailing P/E near 39x. Balance-sheet leverage is high, with roughly $7.7 billion of debt against about $1.6 billion of cash and a very small book equity base. VVVV: Almost all revenue comes from one product family, and in the U.S. nearly all of it flows through one distributor: Henry Schein accounted for about 90% of sales in the first half of 2026, up from 62% a year earlier, under an exclusive agreement that runs to December 31, 2029. Heartland Dental, a large dental service organization, is another key customer. Curodont Repair Fluoride Plus is sold under the FDA's over-the-counter route because of its fluoride, and the company itself warns regulators could disagree with that classification and require a different pathway. Dentists already have entrenched, reimbursed options in fluoride varnish, sealants and fillings, and the clinical case for Curodont rests largely on European studies. The company is still losing money, with an accumulated deficit of ~$256.3 million, and carries expensive floating-rate debt. Governance is concentrated: the Abivardi sisters hold all the Class B voting shares and about 87% of voting power, and they have pledged about 10.3 million shares as collateral for CHF 105 million (~$128 million) of personal loans, with talks to pledge up to 2.87 million more. A forced sale of pledged shares would land on the public float. The stock has traded for only a week, priced below its range, has since fallen about 18% under the offer price, and faces a 180-day lock-up expiry in May 2027. It has no analyst coverage yet, and it will report its first full quarter as a public company in 2027.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CL or VVVV; figures are approximate and dated (as of November 2026). Verify current data before investing.